表紙:KRAS阻害薬 - 市場機会、疫学・市場予測、パイプライン、競合分析:2020年~2030年
市場調査レポート
商品コード
945512

KRAS阻害薬 - 市場機会、疫学・市場予測、パイプライン、競合分析:2020年~2030年

KRAS Inhibitors - Market Opportunity, Epidemiology & Market Forecast, Pipeline and Competitive Analysis, 2020-2030

出版日: | 発行: Mellalta Meets LLP | ページ情報: 英文 2 PDFs: 121 Pages + 30 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.68円
KRAS阻害薬 - 市場機会、疫学・市場予測、パイプライン、競合分析:2020年~2030年
出版日: 2020年06月30日
発行: Mellalta Meets LLP
ページ情報: 英文 2 PDFs: 121 Pages + 30 Pages
納期: 即納可能 即納可能とは
担当者のコメント
当レポートは、別途「KRAS Mutated Cancers Clinical Trials Landscape Therapies under investigation for KRAS Mutated Cancers」レポート30ページが付属されます。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

KRAS(V-Ki-ras2キルステンラット肉腫ウイルス腫瘍遺伝子ホモログ)変異は、がん患者の医学的決定に直接影響を与える可能性があります。KRAS変異は、がんの最大25%に存在しますが、発がん性変異体は多くのがんで異なる有病率を持っています。

当レポートでは、KRAS阻害薬市場について調査分析し、市場機会、疫学・市場予測、パイプライン、競合分析について、体系的な情報を提供しています。

対象企業

  • 1. Silenseed
  • 2. Amgen
  • 3. Gilead
  • 4. Mirati Therapeutics
  • 5. Johnson & Johnson
  • 6. Merck, Moderna Therapeutics
  • 7. Oblique Therapeutics
  • 8. Johnson & Johnson
  • 9. Aurigene
  • 10. Cotinga Pharmaceuticals
  • 11. Codiak Biosciences
  • 12. Mirati Therapeutics
  • 13. Revolution Medicines
  • 14. Boehringer Ingelheim
  • 15. Bayer
  • 16. Sanofi/X-Chem
  • 17. X-Chem
  • 18. BridgeBio Pharma
  • 19. その他

目次

第1章 概要

第2章 要点

第3章 KRAS標的の背景

第4章 適応の優先順位

  • がんにおけるKRAS変異型

第5章 KRASがんの疫学

  • 米国・EUにおけるKRAS変異がんの発生率
  • KRAS G12C・KRAS G12Dの頻度:腫瘍タイプ別

第6章 KRASのライセンシングと提携取引

  • KRASのライセンシングの詳細と取引額
  • KRASの買収の詳細と取引額

第7章 KRASのパイプライン情勢

  • KRASのパイプライン分析
  • KRASの臨床試験情勢

第8章 KRASのパイプライン薬のプロファイルと臨床試験分析

  • Amgen:AMG
    • 製品プロファイル・説明
    • 臨床試験
    • 提携
    • その他の開発
  • Mirati:MRTX
    • 製品プロファイル・説明
    • 臨床試験
    • 提携
    • その他の開発
  • Boehringer Ingelheim:BI 1701963
    • 製品プロファイル・説明
    • 臨床試験
    • 提携
    • その他の開発、など

第9章 市場予測

  • Amgen510の販売ポテンシャル
  • 収益機会

第10章 KRASに関するKOLの見解

第11章 今後のイベント

第12章 付録

図表

List of Tables

  • 1. KRAS Oncogenic mutations frequency in human cancers, 2020
  • 2. Global Incidence cases of KRAS mutated Cancers Overview, 2020
  • 3. Incidence cases of NSCLC adenocarcinoma & Frequency of KRAS G12C & KRAS G12D, 2020-2030
  • 4. Incidence cases of Colorectal adenocarcinoma & Frequency of KRAS G12C & KRAS G12D, 2020-2030
  • 5. Incidence cases of Pancreatic adenocarcinoma, & Frequency of KRAS G12C & KRAS G12D, 2020-2030
  • 6. Incidence cases of Endometrial adenocarcinoma, & Frequency of KRAS G12C & KRAS G12D, 2020-2030
  • 7. KRAS Licensing Details and Deal values, 2020
  • 8. KRAS Acquisition Details & Deal Values, 2020
  • 9. Total Products for KRAS Inhibitors by Phase, 2020
  • 10. Total Products for KRAS Inhibitors in Clinical Trials, 2020
  • 11. Amgen 510 Sales Potential by Cancers, 2020-2030
  • 12. Revenue Potential for KRAS inhibitors
  • 13. Upcoming Events for KRAS, 2020

List of Figures

  • 1. The KRAS cycle
  • 2. KRAS Oncogenic mutations frequency in human cancers, 2020
  • 3. Global Incidence cases of KRAS mutated Cancers Overview, 2020
  • 4. Incidence cases of NSCLC adenocarcinoma & Frequency of KRAS G12C & KRAS G12D, 2020-2030
  • 5. Incidence cases of Colorectal adenocarcinoma & Frequency of KRAS G12C & KRAS G12D, 2020-2030
  • 6. Incidence cases of Pancreatic adenocarcinoma, & Frequency of KRAS G12C & KRAS G12D, 2020-2030
  • 7. Incidence cases of Endometrial adenocarcinoma, & Frequency of KRAS G12C & KRAS G12D, 2020-2030
  • 8. KRAS Licensing Details and Deal values, 2020
  • 9. KRAS Acquisition Details & Deal Values, 2020
  • 10. Total Products for KRAS Inhibitors by Phase, 2020
  • 11. Total Products for KRAS Inhibitors in Clinical Trials, 2020
  • 12. Amgen 510 Sales Potential by Cancers, 2020-2030
  • 13. Revenue Potential for KRAS inhibitors
  • 14. Upcoming Events for KRAS, 2020
目次
Product Code: MM202002

This KRAS report covers the KRAS market opportunity providing key competitive analysis, 37 companies with pipeline drug profiles, clinical trials, upcoming events, other Developments (Collaborations Details, Funding, etc.), Epidemiology forecast of Cancers with KRAS mutation and % of mutation frequency, licensing and deals, as well as presenting market forecast from 2019 to 2030.

Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation may directly influence medical decisions in patients with carcinomas as demonstrated by the recent research. Despite its discovery over three decades ago, it's remained elusive as a drug target, although several downstream mediators are effectively drugged. KRAS itself is described collectively of the master switches for cancer and is especially associated as a driver for Colorectal Carcinoma (CRC), Non-small Lung cancer (NSCLC), and carcinoma.

While KRAS mutations are present in up to 25% of cancers, the oncogenic variants have different prevalence rates in numerous cancers. As per the American Cancer Society, around 200,000 patients are diagnosed every year with lung adenocarcinomas. That puts the KRAS-G12C population within the USA at 14,000-28,000 patients annually. within the case of KRAS-G12C-positive colorectal cancer (CRC), closer to 3000 patients are diagnosed every year.

Amgen certainly has a headstart over its potential opponents, and it is unlikely that a competitor would have the option to sling in front of an expedited development program for AMG 510. Mirati Therapeutics, another competitor, entered the clinic with the KRAS-G12C inhibitor MRTX849, followed by other companies. While there is already a lot of excitement about the new drug, the number of patients who have been treated with it is relatively small.

This KRAS report covers the KRAS market opportunity providing key competitive analysis, 20+ company with pipeline drug profiles, clinical trials, upcoming events, other Developments (Collaborations Details, Funding, etc.), Epidemiology forecast of Cancers with KRAS mutation and % of mutation frequency, licensing and deals, as well as presenting market forecast from 2019 to 2030.

Key Takeaways from the Report:

  • Indication Prioritization: KRAS Mutation patterns in cancers
  • KRAS Mutated Cancers Epidemiology Forecast from 2019-2030
  • Business Transactions & Strategies: Key collaborations and deal values
  • Pipeline Development: Product Profiles, Clinical Trials & Results
  • Market Forecast of KRAS Inhibitors from 2019-2030
  • Recent & Upcoming events

Comapnies covered:

  • 1. Silenseed
  • 2. Amgen
  • 3. Gilead
  • 4. Mirati Therapeutics
  • 5. Johnson & Johnson
  • 6. Merck, Moderna Therapeutics
  • 7. Oblique Therapeutics
  • 8. Johnson & Johnson
  • 9. Aurigene
  • 10. Cotinga Pharmaceuticals
  • 11. Codiak Biosciences
  • 12. Mirati Therapeutics
  • 13. Revolution Medicines
  • 14. Boehringer Ingelheim
  • 15. Bayer
  • 16. Sanofi/X-Chem
  • 17. X-Chem
  • 18. BridgeBio Pharma
  • 19. Others

TABLE OF CONTENTS

1. OVERVIEW

2. KEY TAKEAWAYS

3. The KRAS Target BACKGROUND

4. Indication Prioritization

  • KRAS Mutation patterns in cancers

5. KRAS CANCERS EPIDEMIOLOGY

  • Incidence for KRAS Mutated Cancers in the US and EU
  • Frequency of KRAS G12C & KRAS G12D by Tumour Type

6. KRAS LICENSING AND COLLABORATION DEALS

  • KRAS Licensing Details and Deal values
  • KRAS Acquisition Details & Deal Values

7. KRAS PIPELINE LANDSCAPE

  • KRAS Pipeline Analysis
  • KRAS Clinical Trial Landscape

8. KRAS PIPELINE DRUG PROFILES & CLINICAL TRIAL ANALYSIS

  • Amgen: AMG 510
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • Mirati: MRTX 849
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • Boehringer Ingelheim: BI 1701963
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • List of drugs continued...

9. Market Forecast

  • Amgen 510 Sales Potential
  • Revenue Opportunity

10. KOL VIEWS ON KRAS

11. UPCOMING EVENTS

12. Appendix